Medical Device Maker's IPO a Modest Success

Health and Healthcare

Published: April 16, 2014 1:05 pm

Last Updated: April 28, 2020 1:30 am

Some initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its IPO date. To some, though, that’s an unsuccessful launch from the company’s point of view because the firm left a lot of money on the table. But what about an IPO that prices below its expected range and then posts a modest gain on its first trading day?

That is the situation with Trivascular Technologies Inc. (NASDAQ: TRIV), which sold 6.5 million shares at $12 a share Wednesday morning, below its expected price range of $13 to $15. The company makes medical devices to treat abdominal aortic aneurysms. The company plans to use about $4.6 million of the proceeds to pay off a note to Boston Scientific. The remainder of the proceeds will be used to expand Trivascular’s sales and marketing efforts for its Ovation stent system.

Underwriters for the offering are J.P. Morgan and Credit Suisse. The company’s revenues rose from around $5.4 million in 2012 to $19.5 million in 2013. Net losses rose too, from $43.3 million to $50.3 million. Among its competitors are Medtronic Inc. (NYSE: MDT) and Endologix Inc. (NASDAQ: ELGX).

ALSO READ: Two IPOs Show IPO Market Losing Luster

Investors are wary of the increased expenditures in marketing, considering the company has already piled up nearly $240 million in debt. The potential market for the product is expected to rise from $1.4 billion in 2012 to $1.6 billion in 2016. But the competition is stiff and Trivascular faces an uphill battle.

Shares were up 3.5% in the noon hour on Wednesday to $12.42, after trading in a range of $11.17 to $12.54 on its opening day.

Quotient Ltd., a commercial-stage medical diagnostics firm, was also expected to fire off its IPO Wednesday, but that does not appear to be an expectation met by action. There is always tomorrow.

ALSO READ: City Office, Paycom IPOs Get No Traction

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.